NAD recommends Maximum Human Performance tone down its advertising for MYO-X Myostatin Inhibitor
NEW YORK — The National Advertising Division last week recommended that Maximum Human Performance, which markets the dietary supplement MYO-X Myostatin Inhibitor, discontinue the advertising claims and testimonials at issue in NAD’s review.
As part of NAD’s routine monitoring efforts, and in conjunction with an initiative with the Council for Responsible Nutrition designed to expand NAD’s review of advertising claims for dietary supplements, NAD requested substantiation for claims that appeared in print advertising, on product packaging and on the advertiser’s website, including: “Research has shown that a reduction in serum myostatin levels is likely to result in clinically significant muscle gains. In my work with elite athletics I have seen firsthand the muscle enhancement impact of MYO-X when used in conjunction with intense weight training. These athletes have made vast improvements in muscle size, strength, performance and improved recovery.”
The advertiser explained that MYO-X is a beverage mix dietary supplement formulated to reduce the levels of a biological molecule called myostatin, which inhibits muscle differentiation and growth.
As support for its advertising claims, NAD noted, the company relied on scientific literature and studies that did not address whether ingesting the product did in fact reduce myostatin levels in a manner that resulted in “clinically significant” muscle gains or muscle performance benefits.
NAD noted that while the evidence in the record “shows promising results in support of the theory that ingestion of MYO-X will reduce human myostatin levels and result in a muscle enhancement impact, the evidence fails to establish the causal link necessary to support the claims at issue.”
Following its review, NAD recommended that the advertiser discontinue express claims and testimonials at issue.
The company, in its advertiser’s statement, said it “appreciated the opportunity to participate in the self-regulatory process, however, the company and the leading researcher on the benefits of Myostatin suppression disagrees with the NAD’s assessment of the underlying science and initial studies behind MYO T-12.”
However, the company said, it “will modify its claims to conform to NAD’s decision and will develop claims based on the outcome of future clinical studies.”
Overall, Okinawa Life passes muster with ERSP
NEW YORK — The Electronic Retailing Self-Regulation Program last week determined that Kowa Health Care America can support general performance claims for Okinawa Life, a dietary supplement marketed as providing a variety of health benefits.
“Kowa Health Care America appreciates the opportunity to participate in the Electronic Retailing Self-Regulation Program’s self-regulatory process, and we welcome ERSP’s decision regarding advertising for the Okinawa Life dietary supplement," the company stated. "We are pleased ERSP determined that scientific evidence demonstrates that the soy isoflavones in Okinawa Life support lower cholesterol levels, improved endothelial function and cardiovascular health. We will modify advertising for Okinawa Life in accordance with ERSP’s recommendations.”
While Kowa provided support for claims regarding the nutritional benefits of soy isoflavones, ERSP determined that claims related to zedoary and goya were not adequately supported. As a result, ERSP recommended Kowa modify its advertising to discontinue references to goya and zedoary in a context that implies to consumers that the dosages of these ingredients in Okinawa Life are nutritionally beneficial.
ERSP is an investigative unit of the advertising industry’s system of self-regulation and is administered by the Council of Better Business Bureaus. The marketer’s advertising came to the attention of ERSP pursuant to its ongoing monitoring program.
Bayer HealthCare consolidates office buildings to new Whippany, N.J., facility
WHIPPANY, N.J. — Bayer HealthCare last week moved into its new U.S. headquarters on a 94-acre campus here, consolidating Bayer HealthCare’s operations that previously operated from Morristown, Montville and Wayne, N.J., and Tarrytown, N.Y., into one location.
Housed in two buildings connected by a five-story glass atrium, the 700,000-sq.-ft. office space features state-of-the-art technology and a modern open design for the approximately 2,400 employees now based at the new location.
"Bayer HealthCare is honored to now be a part of a community where we can continue to grow and thrive. We have a longstanding history of favorable results in research and development that has led to innovative products that make people’s lives better," stated Phil Blake, president of Bayer Corporation. "The opening of our new headquarters culminates the incredible year that Bayer has experienced, with the introduction of five new drugs ranging from oncology to women’s health care to cardiovascular."